

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
3 July 2003 (03.07.2003)

PCT


(10) International Publication Number
WO 03/053950 A1

- (51) International Patent Classification⁷: C07D 319/06 (74) Agent: KOREANA PATENT FIRM; Dong-kyong Bldg. 824-19, Yoksam-dong, Kangnam-ku, 135-080 Seoul (KR).
- (21) International Application Number: PCT/KR02/01540 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 13 August 2002 (13.08.2002)
- (25) Filing Language: Korean
- (26) Publication Language: English
- (30) Priority Data:
2001/81659 20 December 2001 (20.12.2001) KR (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*):
CHOONGWAE PHARMA CORPORATION [KR/KR];
698, Sindae-bang-dong, Dongjak-gu, 156-010 Seoul (KR).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): LEE, Inhee [KR/KR]; No. 130-606, Hwanggol Maeul Jugong Apartment, Yeongtong-dong, Padal-gu, 442-740 Suwon-si, Gyeonggi-do (KR). LEE, Seungjoo [KR/KR]; No. 404, Seongwon-jutaek, Ilwol-jigu, Guun-dong, Gwonseon-gu, 441-340 Suwon-si, Gyeonggi-do (KR).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*


(54) Title: NEW PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE 2-[6-(SUBSTITUTED ALKYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES



(I)



(II)



(III)

(57) Abstract: The present invention relates to new process for preparing as a key chiral intermediate compound of formula (I) obtained from an epoxy-β-hydroxy carboxylic acid ester of formula (II) prepared from epoxide compound of formula (III), in which said compound of formula (I) is useful for preparing the therapeutic agent for hyperlipidemia, such as Astrovastatin and Fluvastatin. Wherein R₁ denotes a hydrogen atom, alkyl, aryl or alkylaryl, R₂ and R₃ which can be identical or different, are a lower alkyl or phenyl and are capable of forming a six-membered ring, R₄ stands for hydroxy, amino, alkylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc.

WO 03/053950 A1

DT09 Rec'd PCT/PTO 21 JUN 2004

**NEW PROCESS FOR THE PREPARATION OF OPTICALLY ACTIVE
2-[6-(SUBSTITUTED ALKYL)-1,3-DIOXAN-4-YL]ACETIC ACID DERIVATIVES**


TECHNICAL FIELD

5

The present invention relates to a process for preparing intermediates of pharmaceuticals, especially Statin-type pharmaceuticals such as Atrovastatin and Fluvastatin etc. or optically active 2-[6-(substituted alkyl)-1,3-dioxane-4-yl] acetic acid derivatives which are valuable as an intermediate of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA reductase) repressor.

More specifically, the present invention relates to a new process for preparing a compound of formula (I) by reacting optically active epoxy alcohol of formula (II) prepared from an optically active epoxy compound of formula (III) with various substituents.

15 [Scheme 1]



wherein R₁ denotes a hydrogen atom, alkyl, aryl or alkylaryl, preferably methyl, ethyl, isopropyl, or *tert*-butyl, R₂ and R₃ which can be identical or different, denote a lower alkyl or phenyl and are capable of forming a six-membered ring, R₄ stands for hydroxy, amino, alkylamino, arylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl,

20

alkenyl, aryl, or aminomethyl, etc.

BACKGROUND ART

5 The following processes for the preparation of optically active 2-[6-(substituted alkyl)-1,3-dioxane-4-yl] acetic acid derivatives represented by the above formula (I) are well known in the prior art.

(1) The process for the synthesis of optically active 2-[6-(hydroxy methyl)-1,3-dioxane-4-yl] acetic acid derivatives from 3-hydroxy- γ -butyrolactone via 3,5-dihydroxyhexane acid ester derivatives (Japanese Laid Open Patent Publication No.(Hei)4-173767).

(2) The process for the synthesis of optically active 2-[6-(cyano methyl)-1,3-dioxane-4-yl] acetic acid derivatives from 3-hydroxy-4-bromoester (USP 5155251).

15 (3) The process for the synthesis of 3,5,6-trihydroxyhexane acid ester derivatives from 4-chloroacetic acid ester through transforming to benzyloxy derivatives, reducing and chain-extending (Japanese Laid Open Patent Publication No.(Hei)6-65226).

(4) The process for the synthesis of optically active 2-[6-(substituted alkyl)-1,3-dioxane-4-yl] acetic acid derivatives from 4-chloro-3-hydroxybutyric acid ester through chain-extending and reducing, etc. (USP 5278313).

20 (5) The process for the synthesis of 3,5,6-trihydroxyhexane acid ester derivatives from malic acid via 2,4-dihydroxyadipic acid derivatives (Japanese Laid Open Patent Publication No.(Hei)4-69355).

However, since the aforementioned comprise the reactions under extremely low temperature such as around -80°C (Processes 1, 2, 4 and 5) or the reaction of



hydrogenation under the high pressure of 100 k/cm² (Process 3), they should need a particular device for the reaction. Further, the processes use a high-priced reagent such as LDA in a part of steps or others, and the starting materials used can hardly produce various derivatives or need other operations and thus have a problem to require a long reaction course. Conclusively, any one of the processes cannot be effective in the commercial scale.

On the other hand, Korean Laid Open Patent Publication No.2001-30819(corresponding to PCT/JP1999/04299) has disclosed a process for preparing 2-[6-(substituted methyl)-1,3-dioxane-4-yl] acetic acid derivatives from low-cost materials without the need of a particular device such as a device for extremely low temperature reaction. However, the process give rise to problems of the purification of the final diol-based compounds and industrialization since it includes a stage of producing optically active diol compounds by use of microbial strands as a key step. Besides the aforementioned process can hardly produce various derivatives because of employing microbial strands.

The Statin-type pharmaceuticals such as Atrovastatin and Fluvastatin include compounds with optically active 1,3-diol unit. Therefore, there is a continuing need for a low-cost and simple process for preparing compounds comprising optically active 1,3-diol unit as a chiral building block, e.g., optically active 2-[6-(substituted alkyl)-1,3-dioxane-4-yl] acetic acid derivatives.

We have endeavored to solve the above issue. As a result, we have discovered that the optically active 2-[6-(substituted alkyl)-1,3-dioxane-4-yl] acetic acid derivatives of the following formula (I) could be produced efficiently according to a scheme which had not been publicly known. In the course of the above study, we have also discovered that a

new process for producing β -hydroxyepoxycarboxylic acid derivative of formula (II) as other intermediates for preparing various compounds of formula (I) can be developed.



5 wherein R_1 denotes a hydrogen atom, alkyl, aryl or alkylaryl, preferably methyl, ethyl, isopropyl, or *tert*-butyl, R_2 and R_3 which can be identical or different, denote a lower alkyl or phenyl and are capable of forming a six-membered ring, R_4 stands for hydroxy, amino, alkylamino, arylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc.

10 In addition, we have discovered a method for preparing various compounds of formula (I) by reacting β -hydroxyepoxycarboxylic acid derivative of formula (II) with various nucleophilic reagents.

Therefore, it is a first object of the present invention to provide a process for preparing the compound of formula (I).

15 It is a second object of the invention to provide a process for preparing the compound of formula (II) as the intermediate to produce the compound of formula (I).

DETAILED DESCRIPTION

20 In the present invention, the process for preparing the compound of formula (I) as shown in Scheme 2, characterized in that it comprises the following steps of:

(a) reacting an epoxide compound of formula (III) with vinyl magnesium bromide or

vinyl magnesium chloride to produce a β -hydroxy compound of formula (IV);

(b) protecting the hydroxy group of β -hydroxy compound of formula (IV) with a alkyloxy carbonyl group by reacting the β -hydroxy compound of formula (IV) with dialkyldicarbonate such as di-*tert*-butyl dicarbonate to produce a compound of formula
5 (V);

(c) cyclization-reacting the compound of formula (V) by a iodolactone forming reaction to produce a compound of formula (VI);

(d) treating the compound of formula (VI) with a weak base such as K_2CO_3 , Na_2CO_3 to produce a compound of formula (II);

10 (e) producing a 1,3-diol compound of formula (VII) by a ring opening reaction of the compound of formula (II) with various nucleophiles in the presence of a metal catalyst and a phase transition catalyst;

(f) treating the 1,3-diol compound of formula (VII) with an acetylating agent or a ketalizing agent in the presence of an acid catalyst to transform the compound of formula
15 (VII) into a compound of formula (VIII); and

(g) if necessary, producing a compound of formula (I) by exchanging R'_4 group in the compound of formula (VIII).

Also, the present invention provides the process for preparing the compound of formula (II) as the intermediate as shown in Scheme 2, characterized in that it comprises
20 the following steps of:

(a) reacting an epoxide compound of formula (III) with vinyl magnesium bromide or vinyl magnesium chloride to produce a β -hydroxy compound of formula (IV);


(b) protecting the hydroxy group of β -hydroxy compound of formula (IV) with an alkyloxy carbonyl group by reacting the β -hydroxy compound of formula (IV) with

dialkyldicarbonate such as di-*tert*-butyl dicarbonate to produce the compound of formula (V);

(c) cyclization-reacting the compound of formula (V) to produce a compound of formula (VI); and

5 (d) treating the compound of formula (VI) with a weak base such as K_2CO_3 , Na_2CO_3 to produce a compound of formula (II).

[Scheme 2]




10 wherein R_1 denotes a hydrogen atom, alkyl, aryl or alkylaryl, preferably methyl, ethyl, isopropyl, or *tert*-butyl, R_2 and R_3 which can be identical or different, denote a lower alkyl or phenyl and are capable of forming a six-membered ring, R_4 stands for hydroxy, amino, alkylamino, arylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc. and R'_4 is the same as R_4 or a group having the

15 precursor form thereof.

Embodiments of the present invention are shown in the following Schemes 3 and 4.


【Scheme 3】



wherein R_1 denotes a hydrogen atom, alkyl, aryl or alkylaryl, preferably methyl, ethyl,

5 isopropyl, or *tert*-butyl.

【Scheme 4】



wherein R₁ denotes a hydrogen atom, alkyl, aryl or alkylaryl, preferably methyl, ethyl, isopropyl, or *tert*-butyl, R₂ and R₃ which can be identical or different, denote a lower alkyl or phenyl and are capable of forming a six-membered ring, R₄ stands for hydroxy, amino, 5 alkylamino, arylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc. and R'₄ is the same as R₄ or a group having the precursor form thereof.

The groups of alkyl, aryl and alkylaryl used in the present invention include C₁₋₁₂ alkyl, C₁₋₆ alkyl, and C₆₋₁₂ alkylaryl respectively, but are not limited to them. 10

The term "precursor form" means a chemical which is intended to include, e.g., the precursor form of an aminomethyl group is a cyano group, and that of a hydroxy group is an acetoxyl or benzyloxy group and vice versa.

The present invention is more specifically explained as follows.

In Steps (a) and (b) of Scheme 3, an epoxide compound of formula (III) or a β - hydroxy compound of formula (IV) is available from commercial compounds or materials produced by conventional methods described in the literatures(See Science 1997, 277, 936-
5 938 ; JACS. 2000, 122, 1235-1236 ; TL. 1986, 27, 5791 ; JOC. 1988, 63, 1961-1973 ;
Manufacturer : CHOONGWAE PHARMA CO.).

In Step (b), a β -hydroxycarboxylic ester of formula (IV) is reacted with dialkyl dicarbonate such as di-*tert*-butyl dicarbonate[(Boc)₂O] in the presence of a base and an organic solvent to produce a carbonate compound of formula (V). The base used in the
10 reaction includes chemical reagents whereby a carbonate compound is produced from alcohol are generally used, but is not limited to them. Examples of a base which can be used in the presence of organic solvents, include metal base such as methyl lithium, n-butyl lithium, sodium hydride, or triethylamine, pyridine, diisopropylamine, isopropylethylamine, and a catalytic amount of N,N-dimethylaminopyridine. The reaction is carried out at
15 temperature between -78°C and 100°C, particularly at low temperature of -30°C ~ 0°C in some cases of using a metal base.

In Step (c), an iodation reaction proceeds at the double bond position in the compound of formula (IV) by reacting the compound of formula (V) with IBr dissolved dichloromethane in the presence of toluene solvent at low temperature of -80°C, according
20 to a conventional method(See JOC., 1993, 58, 3703-3711). Then, the iodo-lactonation forming reaction proceeds by the internal substitution via oxygen atom of the alkyloxy carbonyl group corresponding to a hydroxy-protecting group to produce 1,3-*cis* compound of formula (VI) and 1,3-*trans* compound of formula (VI-a) in the ratio of 18 : 1 ~ 21 : 1(See the above reference).


However, in the proceeding of the reaction, the ratio of *cis/trans* is rendered unfavorable at the temperature of -80°C or higher, and if the mixture is added IBr which dissolved dichloromethane, it is difficult to add IBr drop by drop because IBr is salted out at the low temperature. These problems can be solved by trifluoromethylbenzene instead of dichloromethane for dissolving IBr. Generally, the reaction temperature is appropriate between -80°C and 0°C . Particularly, the highest ratio of *cis/trans* (i.e. 20/1 to 24/1) appears at temperature between -30°C and -20°C .

Therefore, the present invention provides excellent processes without problems caused from use of low temperature in the prior arts. Further, trifluoromethylbenzene itself or mixed solvents with commercial organic solvents can be used. Particularly, examples of preferable solvents which can be used together with trifluoromethylbenzene, include toluene or benzene.

In Step (d), the ring-opening reaction of the six-membered ring and the cyclization for epoxide ring-forming reaction are proceeded concurrently under the basic condition.

However, where a compound having an acidic proton at the α -position such as the compounds of formula (VI) are reacted with basic reagent at room temperature, α, β -unsaturated epoxide of formula (II-a) is produced by the α, β -removal reaction as shown in Scheme 5 instead of the desired compound of formula (II).

【Scheme 5】



As a result of using many reagents under the various condition, it has been discovered that desired compound of formula (II) can be obtained good selectivity and improved yield by using weak base reagents such as 3 equivalents of potassium carbonate/methanol or

sodium carbonate/methanol at temperature between -78°C and 0°C , preferably between -30°C and 0°C .

It is somewhat difficult to produce various compounds of formula (I) as required in the prior arts. However, according to the present invention, the compound of formula (I) from the compound of formula (II) produced as another intermediate can be produced. Accordingly, it is a merit of the invention that various compounds of formula (I) are conveniently produced according to reagents.

In Step (e) of Scheme 4, various substituents can be attached to the compound of formula (II) by the ring-opening reaction through using various kinds of nucleophilic reagents.

Examples of reagents which can be used to attach various substituents in said step include commercial reagents for epoxide ring-opening reaction, but are not limited to them. For instance, cyanide, halide, alkoxide and an azide compound of alkali metal, Grignard reagent, organometal compound or the like can be reacted under an organic solvent with metallic catalysts, acids and a phase transition catalysts.

Examples of metallic catalysts, include titanium isopropoxide[$\text{Ti}(\text{O}^i\text{Pr})_4$], aluminium isopropoxide[$\text{Al}(\text{O}^i\text{Pr})_3$], trifluoroboron diethylether[$\text{BF}_3 \cdot \text{OEt}_2$]. The metallic catalysts can be used in the amount of 0.1 times to 100 times in equivalents, preferably 0.5 times to 50 times in equivalents, more preferably 1 times to 10 times in equivalents based on the amount of the compound of formula (II).

Examples of phase transition catalysts, include crown ether, quaternary ammonium halide or quaternary potassium halide and can be added in the amount of 0.1 times to 100 times in equivalents, preferably 0.5 times to 50 times in equivalents, more preferably 1 times to 10 times in equivalents based on the amount of the compound of formula (II).

The reaction is carried out generally at temperature between -50°C and 100°C , preferably between 0°C and 50°C , more preferably between 10°C and 30°C .

In Step (f), the compound of formula (VIII) having 1,3-dioxane ring can be obtained by protecting the 1,3-diol compound of formula (VII) with, for instance, acetone/CSA or
5 dimethoxypropane/CSA etc.

In Step (g), the resulting compound of formula (VIII) is, if necessary, transformed to various derivatives by exchanging the group of R'_4 . For example, when R'_4 is a cyano compound, the compound of formula (I-a) in which R'_4 is exchanged to an amino methyl group can be obtained by treating the compound of formula (VIII) with hydrogen gas
10 atmosphere in the presence of Raney nickel under 40°C and 50 psi in the same manner as in Step (g-1), and when R'_4 is an acetoxy compound, the compound of formula (I-b) in which R'_4 is exchanged to a hydroxy group can be obtained by treating with a weak base reagent such as potassium carbonate/methanol in the same manner as in Step (g-2).

The merits of the present invention are as follows:

15 First, the compound of formula (II) useful as a chiral building block can be produced from a low-priced optically active epoxide compound, and the various compounds of formula (I) can be produced therefrom;

Second, production costs can be reduced because expensive reagents and complicated devices for the reaction are necessary; and

20 Third, the complex reaction steps are not included and thus, the synthesis reaction are simple.

Brief Description of the Drawings


Fig. 1 is a drawing representing a chemical formula of a key chiral intermediate which is useful as a drug of hyperlipidemia

The present invention is further defined by reference to the following examples described in detail, however these examples are not to be construed to limit the scope of the invention.

Examples

<Example 1>

10 Preparation of (3*R*)-hydroxy-hex-5-en acid *tert*-butyl ester



A round bottom flask was charged with 6.0g(31.52mmol) of CuI and add 500ml of tetrahydrofurane. The mixture was cooled to -20 °C, gradually added drop by drop 410 ml of vinyl magnesium bromide(1.0M in THF, 0.41mol), and then agitated at the same temperature for 30 minutes.

Subsequently, the mixture was agitated for 1 hour together with being gradually adding drop by drop 50g(0.3g, 0.32mol) of (*S*)-*tert*-butyl-3,4-epoxybutanoate (Choongwae Pharma Co.,; *Science* 1997, 277, 936-938 ; JACS. 2000, 122, 1235-1236,) diluted in 100ml of tetrahydrofurane. The reaction solution obtained from mixture was added saturated ammonium chlorides to terminate the reaction. The solution was extracted with ethylacetate and the organic layer was washed with water and brine, and then dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure to give 52g of (3*R*)-hydroxy-hex-5-en acid *tert*-butyl ester. The resulting


compound was used to the subsequent reaction without a stage for another purification.

^1H NMR(300MHz, CDCl_3) δ 1.47(s, 9H), 2.23-2.48(m, 4H), 3.08(1H, -OH), 4.0-4.07(m, 1H), 5.09(s, 1H), 5.14(d, $J=4.18$, 1H), 5.76-5.90(m, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 28.51, 41.28, 42.01, 67.90, 81.68, 118.35, 134.55,
5 172.70.

<Example 2>

Preparation of (3*R*)-*tert*-butoxycarbonyloxy-hex-5-en acid *tert*-butyl ester



10

A 1 liter, round bottom flask was charged with 52g(0.29mol) of (3*R*)-hydroxy-hex-5-en acid *tert*-butyl ester and the chemical was dissolved in 250ml of tetrahydrofuran. The mixture was cooled to -20°C , gradually added drop by drop 116 ml(in 2.5M hexane, 0.29mol) of *n*-butyl lithium and then was agitated for 30 minutes.

15 Subsequently, the reaction solution was gradually added drop by drop 63g(0.29mol) of di-*tert*-butyl dicarbonate dissolved in 100ml of tetrahydrofuran, and then was agitated for 1 hour. To the solution of the reaction was then added water to terminate the reaction. The solution was extracted with ethylacetate, and the organic layer was washed with water and brine, and then dehydrated with anhydrous magnesium sulphate. The solvent was
20 removed under decompressed pressure to obtain a crude compound. The resulting compound was subjected to the column chromatography(hexane : ethylacetate=50 : 1) to give 50.4g of pure (3*R*)-*tert*-butoxycarbonyloxy-hex-5-en acid *tert*-butyl ester(Two stage yield : 56%)


^1H NMR(300MHz, CDCl_3) δ 1.46(s, 9H), 1.49(s, 9H), 2.41(t, $J=7.23$, 2H), 2.48-2.61(m, 2H), 5.05-5.16(m, 3H), 5.73-5.87(m, 1H),

^{13}C NMR(75MHz, CDCl_3) δ 28.18, 38.93, 40.31, 73.19, 81.30, 82.37, 118.95, 133.20, 153.20, 169.80.

5

<Example 3>

Preparation of (4*R*-*cis*)-1,1-dimethylethyl-6-iodomethyl-2-oxo-1,3-dioxane-4-yl)-acetic acid *tert*-butyl ester



10

A 500 ml, round bottom flask was charged with 10.0g(34.92mmol) of (3*R*)-*tert*-butoxycarbonyloxy-hex-5-en acid *tert*-butyl ester and then the chemical was dissolved in 100ml of toluene. The mixture was cooled to -30°C , gradually added drop by drop 10.83g(52.38mmol) of iodomonobromide dissolved in 100ml of trifluoromethylbenzene and then agitated the mixture at the same temperature for 30 minutes.

Next, the mixture was added saturated sodium thiosulphonate solution to terminate the reaction. The solution of the reaction was extracted with ethylacetate and the organic layer was washed with saturated sodium bicarbonate solution, water and brine, and then dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure to obtain a crude compound. The resulting compound was subjected to the column chromatography(hexane : ethylacetate=2 : 1) to give white solid of pure (4*R*-*cis*)-1,1-dimethylethyl-6-iodomethyl-2-oxo-1,3-dioxane-4-yl)-acetic acid 8.67g(yield : 68%) and liquid of 390mg of (4*R*-*trans*)-1,1-dimethylethyl-6-iodomethyl-2-

oxo-1,3-dioxane-4-yl)-acetic acid *tert*-butyl ester.

Cis compound : ^1H NMR(300MHz, CDCl_3) δ 1.48(s, 9H), 1.73-1.85(m, 1H), 2.49-2.62(m, 2H), 2.77(dd, $J=16.6$, 6.08, 1H), 3.26-3.34(m, 1H). 3.41(dd, $J=10.75$, 4.48, 1H), 4.43-4.52(m, 1H), 4.81-4.90(m, 1H).


5 ^{13}C NMR(75MHz, CDCl_3) δ 5.987, 28.522, 33.351, 40.996, 75.20, 82.44, 148.84, 168.96.

Trans compound : ^1H NMR(300MHz, CDCl_3) δ 1.48(s, 9H), 2.17-2.28(m, 1H). 2.32-2.41(m, 1H), 2.57(dd, $J=15.98$, 7.77H), 2.81(dd, $J=16.12$, 6.44, 1H), 3.31(dd, $J=10.5$, 8.71, 1H), 3.47(dd, $J=10.54$, 4.52, 1H), 4.59-4.67(m, 1H), 4.87-4.96(m, 1H).

10

<Example 4>

Preparation of (3*R*)-hydroxy-(4*S*)-oxyranyl-butyric acid *tert*-butyl ester



15 A 100ml, round bottom flask was charged with 3.40g(9.55mmol) of (4*R-cis*)-1,1-dimethylethyl-6-iodomethyl-2-oxo-1,3-dioxane -4-yl)-acetic acid and then the compound was dissolved in 30ml of anhydrous methanol. The mixture was added 4.0g(28.94mmol) of potassium carbonate and agitated at -30°C for 1 hour , and then agitated at 0°C for 4 hours.

20 After the completion of the reaction, the solution of the reaction was extracted with water and ethylacetate and then the organic layer was dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure to obtain a crude compound. The resulting compound was subjected to the column

chromatography(hexane:ethylacetate = 2:1) to give 1.54g of (3*R*)-hydroxy-(4*S*)-oxyranyl-butyrac acid *tert*-butyl ester(yield : 80%).

^1H NMR(300MHz, CDCl_3) δ 1.47(s, 9H), 1.68-1.82(m, 2H), 2.47(d, $J=6.84$, 1H),
2.252(dd, $J=4.96$, 2.67, 1H), 2.79(t, $J=4.93$, 1H), 3.09-3.15(m, 1H). 3.386(d, $J=3.4$, 1H),
5 4.21(s, br, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 28.47, 39.23, 42.41, 46.95, 49.89, 66.60, 81.79, 172.46.

<Example 5>

Preparation of [(*R*-(*R**,*R**)-1,1-dimethylethyl 6-cyano-3,5-dihydroxy hexanate



A 250ml, round bottom flask was charged with 1.15g(5.70mmol) of (3*R*)-hydroxy-(4*S*)-oxyranyl-butyrac acid *tert*-butyl ester and then the chemical was dissolved in 40ml of benzene. Subsequently, the reaction solution was added 3.23g(11.38mmol) of titanium
15 isopropoxide. The mixture was agitated at room temperature for 30 minutes, was added 1.5g(5.70mmol) of 18-crown-6 and 3.70g(5.70mmol) of potassium cyanide and then the reaction solution agitated for 48 hours. To the reaction mixture was added a buffer solution(pH=7.0) to terminate the reaction. The solution of the reaction was extracted with ethylacetate, and the organic layer was washed with a saturated sodium carbonate
20 solution, water and brine, and dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure to obtain a crude compound. The resulting compound was subjected to the column chromatography(hexane : ethylacetate=1 : 2) to give 1.01g of [(*R*-(*R**,*R**)-1,1-dimethylethyl 6-cyano-3,5-dihydroxy


hexanate(yield : 77%).

^1H NMR(300MHz, CDCl_3) δ 1.47(s, 9H), 1.68-1.82(m, 2H), 2.47(d, $J=6.84$, 1H), 2.53(dd, $J=4.96$, 2.67, 1H), 2.78(t, $J=4.93$, 1H), 3.09-3.15(m, 1H), 3.39(1H), 4.21(m, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 26.24, 28.48, 41.21, 42.43, 69.02, 68.25, 82.49, 117.79,
5 172.49.

<Example 6>

Preparation of (4*R*-*cis*)-1,1-dimethylethyl 6-cyanomethyl 2,2-dimethyl-1,3-dioxane -4-acetate



A 100ml, round bottom flask, was charged with 1.0g(4.32mmol) of 6-cyano-(3*R*,5*S*)-dihydroxyl-hexane acid *tert*-butyl ester and then the chemical was dissolved in 20ml of acetone. Next, the reaction solution was added 110mg(0.48mmol) of camphorsulphonic
15 acid and 0.54g(5.18mmol) of 2,2-dimethoxypropane. The mixture was agitated at room temperature for 1 hour.

After the completion of the reaction, acetone from solution was removed under depressed pressure. The mixture was added water, extracted with ethylacetate, and then
20 organic layer was dehydrated with anhydrous magnesium sulphate. The resulting solution was subjected to the column chromatography(hexane : ethylacetate=4 : 1) to give 0.96g of pure (4*R*-*cis*)-1,1-dimethylethyl 6-cyanomethyl 2,2-dimethyl-1,3-dioxane-4-acetate(yield : 83%).

^1H NMR(300MHz, CDCl_3) δ 1.39(s, 3H), 1.46(d, $J=4.05$, 9H), 1.57(s, 4H), 1.76(dt, $J=13.18$, 2.26, 1H), 2.34(dd, $J=15.47$, 6.03, 1H), 2.43-2.53(m, 3H), 4.13-4.17(m, 1H), 4.24-4.33(m, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 19.99, 25.34, 28.48, 30.12, 35.79, 42.71, 66.06, 65.44,
5 81.27, 99.84, 117.16, 170.26.

<Example 7>

Preparation of (4*R*-*cis*)-1,1-dimethylethyl 6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate



In a device of hydrogenation reaction, 0.96g(3.56mmol) of (4*R*-*cis*)-1,1-dimethylethyl 6-cyanomethyl 2,2-dimethyl-1,3-dioxane-4-acetate was dissolved in 15ml of methanol saturated with anhydrous ammonium, 78mg of the activated Raney nickel was added, and
15 then the mixture was treated under hydrogen gas atmosphere at 40 °C under 50psi.


When the reaction was completed after 20 hours, the mixed solution was cooled and filtrated. Then the solvent was concentrated under depressed pressure. Concentrated crude compound was subjected to the column chromatography(ethylacetate : methanol : ammonium hydroxide=30 : 20 : 1) to give 0.89g of pure (4*R*-*cis*)-1,1-dimethylethyl 6-(2-aminoethyl)-2,2-dimethyl-1,3-dioxane-4-acetate (yield : 92%).
20

^1H NMR (300MHz, CDCl_3) δ 1.0-1.2 (m, 1H), 1.22(s, 3H), 1.31 (s, 12H), 1.35-1.45(m, 3H), 2.15(dd, 1H, $J=15.1\text{Hz}$, $J=6.2\text{Hz}$), 2.29(dd, 1H, $J=15.1\text{Hz}$, $J=7.0\text{Hz}$), 2.66(t, 2H, $J=6.6\text{Hz}$), 3.82(m, 1H), 4.12(m, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 19.60, 27.96, 30.00, 36.50, 38.25, 39.79, 42.61, 66.08, 67.18, 80.21, 98.35, 169.82.

<Example 8>

5 Preparation of [(*R*-(*R**,*R**)-1,1-dimethylethyl 6-acetoxymethyl-3,5-dihydroxy hexanate



A 100ml, round bottom flask was charged with 0.5g(2.47mmol) of (3*R*)-hydroxy-(4*S*)-oxyranyl-butyric acid *tert*-butyl ester and then the chemical was dissolved in 15ml of benzene. Subsequently, the solution was added 0.63ml(4.94mmol) of trifluoroboron diethylether. The solution was agitated at room temperature for 30 minutes, and then was added 0.90g of tetrabutylammonium iodide, and the resulting mixture was agitated for 24 hours.

Subsequently, the mixture was added a buffer solution(pH=7.0) to complete the reaction. The solution of the reaction was extracted with ethylacetate, and the organic layer was washed with saturated sodium carbonate solution, water and brine, and then dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure to obtain a crude compound. The resulting compound was subjected to the column chromatography(hexane : ethylacetate=1 : 1) to give 440mg of [(*R*-(*R**,*R**)-1,1-dimethylethyl 6-acetoxymethyl-3,5-dihydroxy hexanate(yield : 68%).

^1H NMR (300MHz, CDCl_3) δ 1.47(s, 9H), 1.61-1.70(m, 2H), 2.1(s, 3H), 2.42(d, $J=6.5$, 2H), 3.70(s, 1H, -OH), 3.85(s, 1H, -OH), 4.02-4.13(m, 3H), 4.22-4.31(m, 1H).

^{13}C NMR(75MHz, CDCl_3) δ 21.28, 28.50, 38.94, 42.79, 68.57, 68.91, 70.23, 82.10, 171.53, 172.42

<Example 9>

Preparation of (4*R-cis*)-1,1-dimethylethyl 6-acetoxymethyl 2,2-dimethyl-1,3-dioxane -4-acetate



A 100ml, round bottom flask was charged with 0.25g(0.95mmol) of [(*R*-(*R**,*R**)-1,1-dimethylethyl 6-acetoxy-3,5-dihydroxy hexanate and then the chemical was dissolved in 10ml of acetone. Subsequently, the solution was added 22mg of camphorsulphonic acid
10 and 0.12g(1.14mmol) of 2,2-dimethoxypropane. The mixture was agitated at room temperature for 6 hours.

After the completion of the reaction, acetone from the solution was removed under depressed pressure. The solution was added water, extracted with ethylacetate, and then
15 the organic layer was dehydrated with anhydrous magnesium sulphate.

The resulting compound was subjected to the column chromatography(hexane : ethylacetate=10 : 1) to give 0.25g of pure (4*R-cis*)-1,1-dimethylethyl 6-acetoxymethyl 2,2-dimethyl-1,3-dioxane-4-acetate (yield : 88%).

¹H NMR (300MHz, CDCl₃) δ 1.39(s, 3H), 1.45(s, 9H), 1.47(s, 3H), 1.54-1.60(m, 2H), 2.08(s, 3H), 2.31(dd, *J*=15.2, 6.4, 1H), 2.46(dd, *J*=15.24, 6.72, 1H), 3.97-4.17(m, 3H),
20 4.34-4.24(m, 1H).

<Example 10>

Preparation of (4*R*-*cis*)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid, 1,1-dimethylethyl ester



2g(0.66mmol) of (4*R*-*cis*)-1,1-dimethylethyl-6-acetoxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate was dissolved in 5ml of methanol. Subsequently, the solution was added 46mg(0.33mmol) of anhydrous potassium carbonate, agitated at room temperature for 30 minutes and then filtrated.

The solvent was removed under decompressed pressure. To the residue was added water and ethyl acetate, and extracted. The organic layer was washed with brine and then dehydrated with anhydrous magnesium sulphate. The solvent was removed under decompressed pressure and subjected to the column chromatography to give 156mg of pure (4*R*-*cis*)-6-(hydroxymethyl)-2,2-dimethyl-1,3-dioxane-4-acetic acid, 1,1-dimethylethyl ester(yield : 92%).


¹H NMR (300MHz, CDCl₃) δ 1.39(s, 3H), 1.44(s, 9H), 1.47(s, 3H), 1.51(t, *J*=2.51, 1H), 1.96(t, *J*=5.7, 1H), 2.31(dd, *J*=15.32, 6.03, 1H), 2.45(dd, *J*=15.31, 6.96, 1H), 3.46-3.53(m, 1H), 3.58-3.65(m, 1H), 3.97-4.05(m, 1H), 4.25-4.34(m, 1H).

What is claimed is :

1. A process for preparing the compound of formula (I) as shown in Scheme 2, characterized in that it comprises the following steps of:

- 5 (a) reacting an epoxide compound of formula (III) with vinyl magnesium bromide or vinyl magnesium chloride to produce a β -hydroxy compound of formula (IV);
- (b) protecting the hydroxy group of β -hydroxy compound of formula (IV) with a alkyloxy carbonyl group by reacting the β -hydroxy compound of formula (IV) with dialkyldicarbonate such as di-*tert*-butyl dicarbonate to produce a compound of formula
- 10 (V);
- (c) cyclization-reacting the compound of formula (V) by a iodolactone forming reaction to produce a compound of formula (VI);
- (d) treating the compound of formula (VI) with a weak base such as K_2CO_3 , Na_2CO_3 to produce a compound of formula (II);
- 15 (e) producing a 1,3-diol compound of formula (VII) by a ring opening reaction of the compound of formula (II) with various nucleophiles in the presence of a metal catalyst and a phase transition catalyst;
- (f) treating the 1,3-diol compound of formula (VII) with an acetylating agent or a ketalizing agent in the presence of an acid catalyst to transform the compound of formula
- 20 (VII) into a compound of formula (VIII); and
- (g) if necessary, producing a compound of formula (I) by exchanging R'_4 group in the compound of formula (VIII):

【Scheme 2】



wherein R_1 denotes a hydrogen atom, alkyl, aryl or alkylaryl, R_2 and R_3 which can be identical or different, denote a lower alkyl or phenyl and are capable of forming a six-membered ring, R_4 stands for hydroxy, amino, alkylamino, arylamino, azido, cyano, halogeno, aryloxy, alkyloxy, arylalkyloxy, alkyl, alkenyl, aryl, or aminomethyl, etc. and R'_4 is the same as R_4 or a group of the precursor form.

2. A process for preparing the compound of formula (II) as the intermediate as shown in Scheme 2, characterized in that it comprises the following steps of:

- 10 (a) reacting an epoxide compound of formula (III) with vinyl magnesium bromide or vinyl magnesium chloride to produce a β -hydroxy compound of formula (IV);
- (b) protecting the hydroxy group of β -hydroxy compound of formula (IV) with an alkyloxy carbonyl group by reacting the β -hydroxy compound of formula (IV) with dialkyldicarbonate such as di-*tert*-butyl dicarbonate to produce the compound of formula (V);
- 15 (c) cyclization-reacting the compound of formula (V) to produce a compound of formula (VI); and
- (d) treating the compound of formula (VI) with a weak base such as K_2CO_3 , Na_2CO_3

to produce a compound of formula (II).

3. The process as claimed in Claim 1, wherein R_4 is $-CH_2NH_2$ or $-OH$, and R'_4 which is the precursor form of R_4 is $-CN$, $-OAc$ or $-OBn$.

5

4. The process as claimed in Claim 1 or 2, wherein R_1 is a methyl, ethyl or *tert*-butyl group, and both R_2 and R_3 are methyl group.

5. The process as claimed in Claim 1 or 2, wherein the reaction of Step (c) is carried
10 out at temperature between $-80^\circ C$ and $0^\circ C$ by IBr dissolved in either trifluoromethylbenzene itself or trifluoromethylbenzen together with an organic solvent such as toluene or benzene.


6. The process as claimed in Claim 1 or 2, wherein the reaction of Step (d) is carried
15 out under 3 equivalents of potassium carbonate/methanol or sodium carbonate/methanol at temperature between $-78^\circ C$ and $0^\circ C$.

7. The process as claimed in Claim 1, wherein the nucleophile used in Step (e) is MCN , $MOAc$ or $MOBn$ (wherein M denotes Li , Na , or K).

20

8. The process as claimed in Claim 1, wherein the metal catalyst used in Step (e) is titanium isopropoxide $[Ti(O^iPr)_4]$, aluminium isopropoxide $[Al(O^iPr)_3]$ or trifluoroboron diethylether $[BF_3.OEt_2]$, and the phase transition catalyst is 18-crown-6, 15-crown-5, 12-crown-4 or tetrabutylammonium halide.

25



INTERNATIONAL SEARCH REPORT

International application No.
PCT/KR02/01540

A. CLASSIFICATION OF SUBJECT MATTER IPC7 C07D 319/06 According to International Patent Classification (IPC) or to both national classification and IPC				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC7 C07D Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Korean Patents and Applications for inventions since 1975 Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAPLUS(STN), CASREACT(STN)				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
A	US 5155251 A(WARNER LAMBERT CO) 13 OCTOBER 1992, SEE THE WHOLE DOCUMENT	1, 3		
A	JP 06-107562 A2(SAGAMI CHEM RES; NISSAN CHEMICAL IND LTD) 19 APRIL 1994, SEE THE WHOLE DOCUMENT, SEE THE WHOLE DOCUMENT	1, 3 - 8		
A	McGarvey, Glenn J.'Sodium nitroprusside-mediated substitution of oxygen for nitrogen at saturated carbon centers', Journal of Organic Chemistry (1986), 51(20), p3913-15, SEE THE WHOLE DOCUMENT	2		
A	Fischer, Gordon C.'Irreducible analogs of mevaldic acid coenzyme A hemithioacetal as potential inhibitors of HMG-CoA reductase. Synthesis of a carbon-sulfur interchanged analog of mevaldic acid pantetheine hemithioacetal', Journal of Organic Chemistry (1985), 50(12), p2011-19	2		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input checked="" type="checkbox"/> See patent family annex.				
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; border: none;"> * Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top; border: none;"> "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family </td> </tr> </table>			* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family			
Date of the actual completion of the international search 28 NOVEMBER 2002 (28.11.2002)		Date of mailing of the international search report 29 NOVEMBER 2002 (29.11.2002)		
Name and mailing address of the ISA/KR Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea Facsimile No. 82-42-472-7140		Authorized officer WON, Ho Joon Telephone No. 82-42-481-5605 		

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/KR02/01540

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 5155251 A	13. 10. 1992	DE 69228073 T2 EP 643689 A1 JP 3241723 B2 AU 667320 B2	10. 06. 1999 22. 03. 1995 25. 12. 2001 21. 03. 1996
JP 06-107562 A2	19. 04. 1994	NONE	